Threshold Pharmaceuticals, Inc. Presents Positive TH-302 Preclinical Results in Three Scientific Presentations At American Association for Cancer Research Annual Meeting

REDWOOD CITY, Calif., April 20, 2009 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (NasdaqCM:THLD - News), today announced multiple preclinical presentations on its clinical stage hypoxia-activated prodrug, TH-302, at the American Association for Cancer Research (AACR) Annual Meeting, being held April 18 to 22, 2009, at the Colorado Convention Center in Denver, CO.